FAIR VALUE REPORT

JOHNSON & JOHNSON · JNJ · OCT 17, 2026 · AFTER RESULTS OF OCT 13, 2026

Is Johnson & Johnson cheap at 38 times earnings?

A beat, a guidance raise and the end of the talc saga - yet the stock lost 5.7% in a day and now trades at 38 times earnings. The model calls it fairly priced; Wall Street sees 11% more. The difference is all about 2027.

FPI VERDICT · OCT 17, 2026

DCF 50% · RELATIVE 30% · CONSENSUS 20%

2.2%

at fair value

PRICE AT PUBLICATION$255.57
FPI FAIR VALUE$261.14
WALL STREET TARGET$284.50

UNCERTAINTY

LOW ±10%

FAIR VALUE BAND

$235.03 – $287.25

PRICE VS BAND

INSIDE THE BAND

Numbers as of publication. Today's fair value and price: JNJ stock page → · How uncertainty is rated →

4 MIN READ

THE REPORT IN 3 POINTS

  • 01J&J beat on adjusted EPS at $2.59 and raised 2026 guidance, yet the stock fell 5.7% the next day.
  • 02The 37.9x trailing P/E reflects one $0.09 quarter; on $11.10 guided EPS the stock trades at 23x.
  • 03FPI fair value is $261.14 versus a $255.57 price, while Wall Street's mean target sits at $284.50.

A beat, a raise, a $5.5 billion settlement - and a 5.7% drop

Johnson & Johnson ($JNJ) delivered the quarter to 27 September 2026 with sales of $25.40 billion, up 5.9%, and adjusted EPS of $2.59 against the $2.52 analysts expected. It raised 2026 guidance for the third time, to $101.2 billion of sales and $11.10 of adjusted EPS at the midpoint. The next day the stock fell 5.7% - the worst reaction to any of its last five earnings reports.

The headline culprit is the reported EPS of $0.09, down from $2.12 in the quarter to September 2025, after the talc resolution, the Firefly Bio charge and the Sail deal costs. The gap between $6.34 billion of adjusted net earnings and $210 million of reported earnings is roughly $6.1 billion. But the $5.5 billion talc number had been public since 27 July 2026, and markets rarely sell a charge they have known about for 11 weeks.

What the market actually repriced is 2027. MedTech grew only 2.5% to $8.64 billion, short of the $8.71 billion expected for the second quarter in a row, with Middle East disruption to orders cited. Stelara biosimilars took about 690 basis points off Innovative Medicine growth. Adjusted pretax margin fell from 35.2% to 30.2% of sales. And management repeated that Firefly and Sail will cut 2027 adjusted EPS by about $1.36 - 12% of what 2026 is guided to earn.

RESULTS VS ESTIMATES · LAST 8 QUARTERS
REPORTEDEPSVS EST.PRICE REACTION
OCT 13, 2026$2.59+2.8%−5.7%
JUL 15, 2026$2.90+2.1%−2.7%
APR 14, 2026$2.70+0.7%+0.9%
JAN 21, 2026$2.460.0%−0.1%
OCT 14, 2025$2.80+1.4%0.0%
JUL 16, 2025$2.77+3.4%+6.2%
APR 15, 2025$2.77+7.4%−0.3%
JAN 22, 2025$2.04+2.5%−1.0%

Johnson & Johnson beat the EPS estimate in 7 of the last 8 quarters. Price reaction is the move on the trading day after the results.

38x earnings on the screen, 23x on guidance

The trailing P/E of 37.9x looks like an overheated stock next to the 21.9x industry median. It is largely an accounting artefact: the trailing figure carries a quarter in which the company earned $0.09 per share. On the $11.10 guidance the price is 23.0x - the kind of multiple the market pays for a steady drug maker, not a bubble. The P/E ratio page explains why one distorted quarter can double a trailing multiple.

The real expansion sits elsewhere. EV/EBITDA has gone from 13.0x at 28 December 2025 to 20.7x; price-to-sales from 5.4x to 6.1x; price to free cash flow from 25.6x to 32.6x. The free cash flow yield - cash generated per dollar of market value - is 3.06% against 4.41% for the industry. That is what a 32.3% one-year gain against 14.9% for the S&P 500 does to a stock whose profit is guided to grow 2.9%.

Fair value $261.14: why the model stops 2.2% above the price

The FPI fair value is $261.14, which puts the $255.57 price 2.2% below it - fairly valued. The DCF leg, half the weight, runs on the $21 billion free cash flow guided for 2026 (3.4% of the $610.67 billion market cap), net debt of about $28 billion, a 16.2% net margin and 14.7% return on invested capital. Both beat the industry (13.6% and 10.1%), and that quality is what keeps the number above the price at all.

The relative leg, 30% of the weight, pulls the number down. At 20.7x EV/EBITDA, the stock trades 41% above the 14.7x industry median and above Amgen at 16.8x, a peer with 11.8% three-year revenue growth against 5.6% here. The analyst leg, 20%, pulls it up with a $284.50 mean target. The blend lands at $261.14 - between the 200-day average of $244.12 and the 50-day average of $265.23. In plain terms: a high-quality business priced as a high-quality business, with no discount left.

PRICE VS FPI FAIR VALUE · 119 DAYS TO PUBLICATIONPRICEFAIR VALUE
$289.77$256.80$223.82
JUN 19OCT 16

Over the 119 days to October 17, 2026 the share price went from $228.37 to $255.57 (+11.9%) and the FPI fair value from $232.73 to $261.14 (+12.2%). The gap moved from 1.9% below fair value to 2.2% below.

Street vs model: $284.50 against $261 - a 9% gap built on 2027

Wall Street counts 21 buy, 16 hold and 3 sell ratings. Targets run from a low of $260 - almost exactly the FPI number - through a median of $280 to a high of $320; the mean of $284.50 sits 8.9% above the model and 11.3% above the price. Post-earnings moves were small and mostly down: on 14 October 2026 RBC Capital cut from $290 to $280 and Wells Fargo from $282 to $275, UBS set $270, Leerink $272, Bernstein $270 on 15 October; Wells Fargo then moved back up to $287 on 16 October. Targets issued in the last month average $277.75 against $286.50 for the last quarter - a 3.1% drift lower.

The gap has one explanation. The Street models a 2027 EPS rebound that absorbs the $1.36 dilution and credits the DePuy Synthes orthopaedics spin-off targeted for mid-2027; the model weighs cash flow already visible and the multiples peers trade at today. Insiders are closer to the model than to the Street: $142.3 million of sales in 12 months against one purchase of $257,688. The CEO sold 123,291 shares for $32.2 million at $261-262 on 13 August 2026 - within a dollar of the fair value.

WALL STREET PRICE TARGETS · 40 ANALYSTS
LOW $260.00HIGH $320.00
PRICE $255.57
FPI $261.14

21 buy · 16 hold · 3 sell. FPI fair value sits inside the Street range, the share price is below the whole range.

Three numbers to watch before 8 December

The up scenario needs 2027 guidance at the Enterprise Business Review on 8 December 2026 that swallows the $1.36 hit and still shows adjusted EPS above $11.10, MedTech back above 4% operational growth, and the talc deal clearing its 95% claimant participation threshold so the first payment of no more than $3 billion in 2027 becomes the final word on a 15-year liability. That is the path to the $280 median target, 9.6% above the price.

The down scenario is another MedTech quarter under 3% on 20 January 2027 (consensus: EPS $2.93, revenue $26.45 billion), 2027 EPS guidance under $11, or a close below the 200-day average at $244.12, 4.5% under the current price. Three signals to track:

  • Full-year 2026 free cash flow at $21 billion - the figure the DCF is built on.
  • $261.14 - the fair value that separates fair from expensive at today's cash flows.
  • The $1.34 quarterly dividend, raised 3.1% on 14 April 2026 for the 64th consecutive year, which yields 2.08% and costs about $13 billion a year against $21 billion of free cash flow - the floor argument if 2027 disappoints.
BULLS SAY · BEARS SAY
BULL CASE$320.00+25%

HIGHEST WALL STREET TARGET

  • 01Reaching $320 needs 2027 guidance on 8 December 2026 that absorbs the $1.36 Firefly and Sail dilution and still clears the $11.10 adjusted EPS guided for 2026.
  • 02On guidance the stock is 23.0x, not the 37.9x trailing multiple distorted by a quarter of $0.09 reported EPS, leaving room for a re-rating.
  • 03Quality supports the premium: a 16.2% net margin and 14.7% ROIC against industry medians of 13.6% and 10.1%, with $21 billion of 2026 free cash flow.
BEAR CASE$235.03−8%

BOTTOM OF THE FPI FAIR VALUE BAND

  • 01MedTech grew only 2.5% to $8.64 billion and missed the $8.71 billion expected for a second straight quarter, the miss that drove the 5.7% drop after 13 October 2026.
  • 02EV/EBITDA has jumped from 13.0x at 28 December 2025 to 20.7x, 41% above the 14.7x industry median, while free cash flow yield sits at 3.06% versus 4.41%.
  • 03Insiders sold $142.3 million over 12 months against one $257,688 purchase, with the CEO selling 123,291 shares at $261-262 on 13 August 2026.

FPI FAIR VALUE $261.14 · FPI fair value of $261.14 sits near the low end of the $235.03 to $320.00 span, because the 20.7x EV/EBITDA relative leg offsets a DCF built on $21 billion of 2026 free cash flow.

FPI fair value blends a discounted cash flow model (50%), relative valuation against sector peers (30%) and analyst consensus (20%), updated daily. How the model works →

TRACK THE NUMBER

Get notified when JNJ's fair value changes

Set your own buy price for JNJ and the app alerts you when the stock reaches it. iOS and Android.

Download on the App StoreGet it on Google Play

MORE JNJ REPORTS

This is the first FPI fair value report on Johnson & Johnson. The next one follows the company's next quarterly results.

MORE REPORTS IN HEALTHCARE

Fair Price Index is for informational purposes only and does not constitute investment advice. Fair value calculations are model-based estimates and may not reflect actual market conditions. Always conduct your own research before making investment decisions.